Clinical Formulations vs Nonmedical Products: Why They Are Not the Same

Why a medicine made and monitored under regulator rules is not the same as a product from an unregulated source, with examples from MDMA, ketamine, esketamine and LSD research.

Content last updated October 22, 2026. This page has not been medically reviewed.

Why this matters

A trial result or an approved label describes one specific product, given in a specific setting. It does not describe every product with a similar name. The same word, such as "ketamine" or "MDMA", can mean a regulated medicine, a compounded preparation or an unregulated powder or tablet. This page explains the differences. It gives no sourcing, preparation or dosing advice.

If someone has taken a product of unknown content and is in danger, call 911 in the United States. For a mental health crisis call or text 988. US Poison Help is 1-800-222-1222. [1]

Three kinds of product

	Regulated clinical or approved product	Compounded or unapproved product	Product from an unregulated source
Example	Spravato (esketamine) nasal spray; Ketalar (ketamine) injection; investigational trial product	Compounded ketamine	Tablets or powders sold as "MDMA" or "ketamine"
Regulator checked identity, strength, quality	Yes, in the approval or investigational process	Not evaluated for safety, effectiveness or quality before marketing	No
Monitoring	Required in label or protocol	Not part of a REMS	None
Contents known	Specified	Varies	May contain other drugs

The table is built from the sources below. [2][3][4]

Not the same as a traditional preparation

A plant or fungus preparation used in a community tradition is a third category again. It is neither a purified clinical product nor an unregulated tablet. See Traditional Preparations vs Isolated Compounds and Clinical Products.

Why results do not transfer

A trial of one formulation, in screened participants with trained staff, cannot be assumed to apply to a different product used elsewhere. NIDA notes that in clinical studies participants are screened for existing mental illness, which is one reason serious mental health complications are rare there. [11]
NIDA also says that poorer mental health outcomes may be more likely outside clinical use, and that many past clinical studies did not adequately assess or report adverse events. [11]
See Clinical Research vs Recreational Use and Screening and Eligibility in Clinical Research.

Frequently asked questions

Is a clinic's ketamine the same as an approved medicine?

Not necessarily. Ketalar is approved as an anesthetic; psychiatric use is off-label, and compounded products are not FDA approved. [12][3]

Is the MDMA in trials the same as street MDMA?

No. Trial MDMA is a defined product given in a supervised protocol. Products sold as MDMA have been found to contain other drugs. [4]

Does a lab test or logo prove what is in a product?

Neither does on its own. NIDA says some contaminants are colorless and odorless and are hard to detect without chemical testing. [11]

Why does the FDA require REMS for Spravato?

Because of the risks of sedation, dissociation, respiratory depression, abuse and misuse. [5]

Where do I find out if a product is approved?

Check the regulator's own label and database, and talk with a health professional. See Talking With a Health Professional.

More details: evidence, limits and cautions

The details behind this page: cautions, limits of the evidence and where sources disagree. Open any note to read it.

What regulators require of clinical products

For investigational psychedelic drugs, the FDA says sponsors must give enough information about chemistry, manufacturing and controls to ensure identification, quality, purity and strength of the drug substance and product at every phase. Products used from phase 2 onward must be made under current good manufacturing practice (CGMP). [2] The FDA also notes that drugs made from highly purified substances from natural sources, or by fermentation, are not treated as botanicals for that purpose. [2]

Approved medicines come with a label. The Spravato label, for example, limits use to certified settings under a restricted program (the REMS), requires monitoring for at least two hours after administration, and carries a boxed warning. [5] Trials add structure too: in MDMA research for PTSD, participants had preparatory and integrative therapy sessions, and the second trial used blinded independent assessors. [6][7] In the LSD anxiety trial the product was a defined investigational formulation given at 22 outpatient research sites. [8]

Even so, these trials had problems. The FDA said MDMA trials had unreliable adverse-event reporting and possible bias, and it did not approve the application. [9] A "clinical" label is not a guarantee of safety or benefit.

Compounded and unapproved products

Compounded drugs, including compounded ketamine products, are not FDA approved, so the FDA has not evaluated their safety, effectiveness or quality before marketing. They have no FDA-approved indications or routes of administration. [3] The FDA says compounded ketamine is not part of a REMS, which does not mean it is safer; without monitoring for sedation, dissociation and changes in blood pressure and heart rate, patients may be at risk of serious adverse events. [3] The FDA says it is not aware of evidence that compounded ketamine is safer, more effective or faster than approved medicines for psychiatric disorders. [3] The FDA's list of compounding risk alerts includes alerts on compounded ketamine nasal spray (February 2022) and compounded ketamine products including oral forms (October 2023). [10] See Medical Approval: What Is and Is Not Approved.

Unregulated products and contamination

NIDA says chemical analyses of drugs sold as MDMA have found other substances, including ketamine, amphetamine, synthetic cathinones, MDA and methamphetamine, and that illegally made opioids such as fentanyl have increasingly been found in the drug supply. [4] NIDA adds that illicitly made psychedelic and dissociative drugs may be contaminated with colorless, odorless fentanyl or other dangerous substances, and that more research is needed on how often this happens. [11] Effects can differ from what a person expects, and taking other substances together can produce effects not seen with one alone. [11] A product's name, color, logo or online description does not show what is inside. See Contamination and Adulteration in Psychoactive Products and Product Quality & Contamination.

References

National Institute on Drug Abuse (NIDA), Ketamine, April 2024. Read 2026-10-22.
US Food and Drug Administration, Psychedelic Drugs: Considerations for Clinical Investigations, Guidance for Industry (dated July 2026). Read 2026-10-22.
US Food and Drug Administration, FDA warns patients and health care providers about potential risks associated with compounded ketamine products, including oral formulations, for the treatment of psychiatric disorders, October 2023 (read in an archived copy of the FDA page dated 2026-05-30: archive link). Read 2026-10-22.
National Institute on Drug Abuse (NIDA), MDMA (Ecstasy/Molly), April 2024. Read 2026-10-22.
US Food and Drug Administration, Spravato (esketamine) nasal spray prescribing information, revised 04/2025. Read 2026-10-22.
Mitchell JM et al., MDMA-assisted therapy for severe PTSD: a randomized, double-blind, placebo-controlled phase 3 study, Nature Medicine 2021 (abstract read). Read 2026-10-22.
Mitchell JM et al., MDMA-assisted therapy for moderate to severe PTSD: a randomized, placebo-controlled phase 3 trial, Nature Medicine 2023 (abstract read). Read 2026-10-22.
Robison R et al., Single Treatment With MM120 (Lysergide) in Generalized Anxiety Disorder: A Randomized Clinical Trial, JAMA 2025 (abstract read). Read 2026-10-22.
US Food and Drug Administration, Complete response letter, NDA 215455 (midomafetamine), August 2024. Read 2026-10-22.
US Food and Drug Administration, Compounding Risk Alerts (content current as of 08/27/2026). Read 2026-10-22.
National Institute on Drug Abuse (NIDA), Psychedelic and Dissociative Drugs. Read 2026-10-22.
US Food and Drug Administration, Ketalar (ketamine hydrochloride) injection prescribing information, revised 03/2026. Read 2026-10-22.

Education, not medical advice. This page is for general information. It does not diagnose or treat any condition and is not a substitute for care from a qualified health professional. Natural does not automatically mean safe. Ask a clinician or pharmacist before changing your care, especially if you take medication, are pregnant or breastfeeding, or have a health condition.